Epigenomic changes associated with impaired norepinephrine transporter function in postural tachycardia syndrome

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

The postural tachycardia syndrome (POTS) is characterised clinically by symptoms of light-headedness, palpitations, fatigue and exercise intolerance occurring with standing and relieved by lying down. Symptoms occur in association with an inappropriate rise in heart rate in the absence of a fall in blood pressure with the assumption of standing. The pathophysiology of POTS is complicated and poorly understood. Plasma norepinephrine (NE) is often elevated in patients with POTS, resulting in consideration of dysfunction of the norepinephrine transporter (NET) encoded by SLC6A2 gene. Whilst some studies have implicated a defect in the SLC6A2 gene, the cause of reduced SLC6A2 expression and function remains unclear. The search to explain the molecular mechanism of NET dysfunction has focused on genetic variation in the SLC6A2 gene and remains inconclusive. More recent studies show epigenetic mechanisms implicated in the regulation of SLC6A2 expression. In this article, we discuss the epigenetic mechanisms involved in SLC6A2 repression and highlight the potential therapeutic application of targeting these mechanisms in POTS.

Original languageEnglish
Pages (from-to)342-355
Number of pages14
JournalNeuroscience and Biobehavioral Reviews
Volume74
DOIs
Publication statusPublished - 1 Mar 2017

Keywords

  • Chromatin
  • Epigenetics
  • Gene regulation
  • Histone modifications
  • MeCP2
  • Norepinephrine transporter
  • Postural tachycardia syndrome

Cite this

@article{055e14d32796428bbdc1040963e83eba,
title = "Epigenomic changes associated with impaired norepinephrine transporter function in postural tachycardia syndrome",
abstract = "The postural tachycardia syndrome (POTS) is characterised clinically by symptoms of light-headedness, palpitations, fatigue and exercise intolerance occurring with standing and relieved by lying down. Symptoms occur in association with an inappropriate rise in heart rate in the absence of a fall in blood pressure with the assumption of standing. The pathophysiology of POTS is complicated and poorly understood. Plasma norepinephrine (NE) is often elevated in patients with POTS, resulting in consideration of dysfunction of the norepinephrine transporter (NET) encoded by SLC6A2 gene. Whilst some studies have implicated a defect in the SLC6A2 gene, the cause of reduced SLC6A2 expression and function remains unclear. The search to explain the molecular mechanism of NET dysfunction has focused on genetic variation in the SLC6A2 gene and remains inconclusive. More recent studies show epigenetic mechanisms implicated in the regulation of SLC6A2 expression. In this article, we discuss the epigenetic mechanisms involved in SLC6A2 repression and highlight the potential therapeutic application of targeting these mechanisms in POTS.",
keywords = "Chromatin, Epigenetics, Gene regulation, Histone modifications, MeCP2, Norepinephrine transporter, Postural tachycardia syndrome",
author = "Khan, {Abdul Waheed} and Corcoran, {Susan J.} and Murray Esler and Assam El-Osta",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.neubiorev.2016.06.015",
language = "English",
volume = "74",
pages = "342--355",
journal = "Neuroscience and Biobehavioral Reviews",
issn = "0149-7634",
publisher = "Elsevier",

}

Epigenomic changes associated with impaired norepinephrine transporter function in postural tachycardia syndrome. / Khan, Abdul Waheed; Corcoran, Susan J.; Esler, Murray; El-Osta, Assam.

In: Neuroscience and Biobehavioral Reviews, Vol. 74, 01.03.2017, p. 342-355.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Epigenomic changes associated with impaired norepinephrine transporter function in postural tachycardia syndrome

AU - Khan, Abdul Waheed

AU - Corcoran, Susan J.

AU - Esler, Murray

AU - El-Osta, Assam

PY - 2017/3/1

Y1 - 2017/3/1

N2 - The postural tachycardia syndrome (POTS) is characterised clinically by symptoms of light-headedness, palpitations, fatigue and exercise intolerance occurring with standing and relieved by lying down. Symptoms occur in association with an inappropriate rise in heart rate in the absence of a fall in blood pressure with the assumption of standing. The pathophysiology of POTS is complicated and poorly understood. Plasma norepinephrine (NE) is often elevated in patients with POTS, resulting in consideration of dysfunction of the norepinephrine transporter (NET) encoded by SLC6A2 gene. Whilst some studies have implicated a defect in the SLC6A2 gene, the cause of reduced SLC6A2 expression and function remains unclear. The search to explain the molecular mechanism of NET dysfunction has focused on genetic variation in the SLC6A2 gene and remains inconclusive. More recent studies show epigenetic mechanisms implicated in the regulation of SLC6A2 expression. In this article, we discuss the epigenetic mechanisms involved in SLC6A2 repression and highlight the potential therapeutic application of targeting these mechanisms in POTS.

AB - The postural tachycardia syndrome (POTS) is characterised clinically by symptoms of light-headedness, palpitations, fatigue and exercise intolerance occurring with standing and relieved by lying down. Symptoms occur in association with an inappropriate rise in heart rate in the absence of a fall in blood pressure with the assumption of standing. The pathophysiology of POTS is complicated and poorly understood. Plasma norepinephrine (NE) is often elevated in patients with POTS, resulting in consideration of dysfunction of the norepinephrine transporter (NET) encoded by SLC6A2 gene. Whilst some studies have implicated a defect in the SLC6A2 gene, the cause of reduced SLC6A2 expression and function remains unclear. The search to explain the molecular mechanism of NET dysfunction has focused on genetic variation in the SLC6A2 gene and remains inconclusive. More recent studies show epigenetic mechanisms implicated in the regulation of SLC6A2 expression. In this article, we discuss the epigenetic mechanisms involved in SLC6A2 repression and highlight the potential therapeutic application of targeting these mechanisms in POTS.

KW - Chromatin

KW - Epigenetics

KW - Gene regulation

KW - Histone modifications

KW - MeCP2

KW - Norepinephrine transporter

KW - Postural tachycardia syndrome

UR - http://www.scopus.com/inward/record.url?scp=85002806662&partnerID=8YFLogxK

U2 - 10.1016/j.neubiorev.2016.06.015

DO - 10.1016/j.neubiorev.2016.06.015

M3 - Review Article

VL - 74

SP - 342

EP - 355

JO - Neuroscience and Biobehavioral Reviews

JF - Neuroscience and Biobehavioral Reviews

SN - 0149-7634

ER -